{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:15:19Z","timestamp":1760148919382,"version":"build-2065373602"},"reference-count":58,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["7R01HL150360- 02","PI20\/01004"],"award-info":[{"award-number":["7R01HL150360- 02","PI20\/01004"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Instituto de Salud Carlos III (ISCIII)","award":["7R01HL150360- 02","PI20\/01004"],"award-info":[{"award-number":["7R01HL150360- 02","PI20\/01004"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antioxidants"],"abstract":"<jats:p>Objectives: Homozygous familial hypercholesteremia (HoFH) is a rare, life-threatening metabolic disease, mainly caused by a mutation in the LDL receptor. If untreated, HoFH causes premature death from acute coronary syndrome. Lomitapide is approved by the FDA as a therapy to lower lipid levels in adult patients with HoFH. Nevertheless, the beneficial effect of lomitapide in HoFH models remains to be defined. In this study, we investigated the effect of lomitapide on cardiovascular function using LDL receptor-knockout mice (LDLr\u2212\/\u2212). Methods: Six-week-old LDLr\u2212\/\u2212 mice were fed a standard diet (SD) or a high-fat diet (HFD) for 12 weeks. Lomitapide (1 mg\/Kg\/Day) was given by oral gavage for the last 2 weeks in the HFD group. Body weight and composition, lipid profile, blood glucose, and atherosclerotic plaques were measured. Vascular reactivity and markers for endothelial function were determined in conductance arteries (thoracic aorta) and resistance arteries (mesenteric resistance arteries (MRA)). Cytokine levels were measured by using the Mesoscale discovery V-Plex assays. Results: Body weight (47.5 \u00b1 1.5 vs. 40.3 \u00b1 1.8 g), % of fat mass (41.6 \u00b1 1.9% vs. 31.8 \u00b1 1.7%), blood glucose (215.5 \u00b1 21.9 vs. 142.3 \u00b1 7.7 mg\/dL), and lipid levels (cholesterol: 600.9 \u00b1 23.6 vs. 451.7 \u00b1 33.4 mg\/dL; LDL\/VLDL: 250.6 \u00b1 28.9 vs. 161.1 \u00b1 12.24 mg\/dL; TG: 299.5 \u00b1 24.1 vs. 194.1 \u00b1 28.1 mg\/dL) were significantly decreased, and the % of lean mass (56.5 \u00b1 1.8% vs. 65.2 \u00b1 2.1%) was significantly increased in the HFD group after lomitapide treatment. The atherosclerotic plaque area also decreased in the thoracic aorta (7.9 \u00b1 0.5% vs. 5.7 \u00b1 0.1%). After treatment with lomitapide, the endothelium function of the thoracic aorta (47.7 \u00b1 6.3% vs. 80.7 \u00b1 3.1%) and mesenteric resistance artery (66.4 \u00b1 4.3% vs. 79.5 \u00b1 4.6%) was improved in the group of LDLr\u2212\/\u2212 mice on HFD. This was correlated with diminished vascular endoplasmic (ER) reticulum stress, oxidative stress, and inflammation. Conclusions: Treatment with lomitapide improves cardiovascular function and lipid profile and reduces body weight and inflammatory markers in LDLr\u2212\/\u2212 mice on HFD.<\/jats:p>","DOI":"10.3390\/antiox12061287","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T02:54:33Z","timestamp":1686884073000},"page":"1287","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Beneficial Effect of Lomitapide on the Cardiovascular System in LDLr\u2212\/\u2212 Mice with Obesity"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7241-9172","authenticated-orcid":false,"given":"Undral","family":"Munkhsaikhan","sequence":"first","affiliation":[{"name":"Department of Physiology, University of Tennessee Health Science Center, Memphis, TN 38163, USA"},{"name":"Department of Bioscience Research and General Dentistry, College of Dentistry, The University of Tennessee Health Science Center, Memphis, TN 38163, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young In","family":"Kwon","sequence":"additional","affiliation":[{"name":"Department of Physiology, University of Tennessee Health Science Center, Memphis, TN 38163, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amal M.","family":"Sahyoun","sequence":"additional","affiliation":[{"name":"Department of Physiology, University of Tennessee Health Science Center, Memphis, TN 38163, USA"},{"name":"Department of Food Science and Agriculture Chemistry, McGill University, Montreal, QC H9X 3V9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4758-8388","authenticated-orcid":false,"given":"Mar\u00eda","family":"Gal\u00e1n","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, University Rey Juan Carlos, 28922 Alcorc\u00f3n, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBERCV), ISCIII, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0323-1448","authenticated-orcid":false,"given":"Alexis A.","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Instituto de Qu\u00edmica, Pontificia Universidad Cat\u00f3lica de Valpara\u00edso, Valpara\u00edso 300, Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karima","family":"Ait-Aissa","sequence":"additional","affiliation":[{"name":"College of Dental Medicine, Lincoln Memorial University, Knoxville, TN 37923, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1826-9377","authenticated-orcid":false,"given":"Ammaar H.","family":"Abidi","sequence":"additional","affiliation":[{"name":"Department of Bioscience Research and General Dentistry, College of Dentistry, The University of Tennessee Health Science Center, Memphis, TN 38163, USA"},{"name":"College of Dental Medicine, Lincoln Memorial University, Knoxville, TN 37923, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Kassan","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Pharmacy, West Coast University, Los Angeles, CA 91606, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9728-063X","authenticated-orcid":false,"given":"Modar","family":"Kassan","sequence":"additional","affiliation":[{"name":"Department of Physiology, University of Tennessee Health Science Center, Memphis, TN 38163, USA"},{"name":"College of Dental Medicine, Lincoln Memorial University, Knoxville, TN 37923, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"569","DOI":"10.7150\/ijbs.14027","article-title":"Dysregulation of the Low-Density Lipoprotein Receptor Pathway Is Involved in Lipid Disorder-Mediated Organ Injury","volume":"12","author":"Zhang","year":"2016","journal-title":"Int. J. Biol. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCULATIONAHA.113.001292","article-title":"Lomitapide and mipomersen: Two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia","volume":"129","author":"Rader","year":"2014","journal-title":"Circulation"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11883-020-00858-4","article-title":"Lomitapide\u2013A Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia","volume":"22","author":"Stefanutti","year":"2020","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"104216","DOI":"10.1016\/j.mvr.2021.104216","article-title":"Assessment of microvascular function and pharmacological regulation in genetically confirmed familial hypercholesterolemia","volume":"138","author":"Pajkowski","year":"2021","journal-title":"Microvasc. Res."},{"key":"ref_5","first-page":"669","article-title":"Familial hypercholesterolemia","volume":"14","author":"Pejic","year":"2014","journal-title":"Ochsner J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1161\/CIRCULATIONAHA.117.028208","article-title":"Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia","volume":"136","author":"Blom","year":"2017","journal-title":"Circulation"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: New insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur. Heart J."},{"key":"ref_8","unstructured":"Adam, M.P., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., Bean, L.J., Gripp, K.W., and Amemiya, A. (1993). GeneReviews\u00ae, University of Washington."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ihj.2019.03.004","article-title":"Lipoprotein(a): An independent, genetic, and causal factor for cardiovascular disease and acute myocardial infarction","volume":"71","author":"Enas","year":"2019","journal-title":"Indian Heart J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11886-021-01565-5","article-title":"Familial Hypercholesterolemia: Global Burden and Approaches","volume":"23","author":"Tokgozoglu","year":"2021","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for Homozygous Familial Hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.atherosclerosis.2012.02.019","article-title":"Homozygous familial hypercholesterolemia: Current perspectives on diagnosis and treatment","volume":"223","author":"Raal","year":"2012","journal-title":"Atherosclerosis"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.atherosclerosissup.2015.02.002","article-title":"Managing homozygous familial hypercholesterolaemia from cradle to grave","volume":"18","author":"Thompson","year":"2015","journal-title":"Atheroscler. Suppl."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/MOL.0000000000000677","article-title":"Homozygous familial hypercholesterolemia: What treatments are on the horizon?","volume":"31","author":"Bajaj","year":"2020","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.hfc.2021.07.008","article-title":"New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia","volume":"18","author":"Cesaro","year":"2021","journal-title":"Heart Fail. Clin."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.atherosclerosis.2018.01.034","article-title":"A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry)","volume":"270","author":"Kayikcioglu","year":"2018","journal-title":"Atherosclerosis"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/978-3-319-48382-5_15","article-title":"Endothelial Dysfunction in Obesity","volume":"960","author":"Engin","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Gamez-Mendez, A.M., Vargas-Robles, H., R\u00edos, A., and Escalante, B. (2015). Oxidative Stress-Dependent Coronary Endothelial Dysfunction in Obese Mice. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0138609"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0163-7258(02)00236-X","article-title":"LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: Implications in endothelial dysfunction and atherosclerosis","volume":"95","author":"Chen","year":"2002","journal-title":"Pharmacol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3389\/fcvm.2018.00130","article-title":"Endothelial Transcytosis of Lipoproteins in Atherosclerosis","volume":"5","author":"Zhang","year":"2018","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Medina-Leyte, D.J., Zepeda-Garc\u00eda, O., Dom\u00ednguez-P\u00e9rez, M., Gonz\u00e1lez-Garrido, A., Villarreal-Molina, T., and Jacobo-Albavera, L. (2021). Endothelial Dysfunction, Inflammation and Coronary Artery Disease: Potential Biomarkers and Promising Therapeutical Approaches. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22083850"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1038\/sj.cdd.4401451","article-title":"Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease","volume":"11","author":"Austin","year":"2004","journal-title":"Cell Death Differ."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Silva, I.V.G., de Figueiredo, R.C., and Rios, D.R.A. (2019). Effect of Different Classes of Antihypertensive Drugs on Endothelial Function and Inflammation. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20143458"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1172\/JCI0216784","article-title":"Translational control in the endoplasmic reticulum stress response","volume":"110","author":"Ron","year":"2002","journal-title":"J. Clin. Investig."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e015878","DOI":"10.1161\/JAHA.120.015878","article-title":"Oxidized Low-Density Lipoprotein Induces Macrophage Production of Prothrombotic Microparticles","volume":"9","author":"Marchini","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1042\/CS20190648","article-title":"Endoplasmic reticulum stress and mitochondrial biogenesis are potential therapeutic targets for abdominal aortic aneurysm","volume":"133","author":"Miyao","year":"2019","journal-title":"Clin. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12929-017-0357-5","article-title":"Role of free fatty acids in endothelial dysfunction","volume":"24","author":"Ghosh","year":"2017","journal-title":"J. Biomed. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"7938","DOI":"10.1038\/s41598-018-26188-9","article-title":"Exercise ameliorates endoplasmic reticulum stress-mediated vascular dysfunction in mesenteric arteries in atherosclerosis","volume":"8","author":"Hong","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/bcp.12612","article-title":"Lomitapide","volume":"80","author":"Goulooze","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1021\/jm000494a","article-title":"A Novel Series of Highly Potent Benzimidazole-Based Microsomal Triglyceride Transfer Protein Inhibitors","volume":"44","author":"Robl","year":"2001","journal-title":"J. Med. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jacl.2019.03.001","article-title":"Case report: The efficacy and safety of lomitapide in a homozygous familial hypercholesterolemic child","volume":"13","author":"Chacra","year":"2019","journal-title":"J. Clin. Lipidol."},{"key":"ref_32","first-page":"344","article-title":"Effectiveness and safety of lomitapide in a patient with familial chylomicronemia syndrome","volume":"71","author":"Giammanco","year":"2020","journal-title":"Endocrine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.athplu.2021.05.001","article-title":"Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile","volume":"43","author":"Lupo","year":"2021","journal-title":"Atheroscler. Plus"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1096\/fasebj.2022.36.S1.0R277","article-title":"The Microsomal Triglyceride Transfer Protein Inhibitor, Lomitapide, Improves Vascular Function in Obesity","volume":"36","author":"Munkhsaikhan","year":"2022","journal-title":"FASEB J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrcardio.2011.2","article-title":"Pharmacological strategies for lowering LDL cholesterol: Statins and beyond","volume":"8","author":"Brautbar","year":"2011","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"115825","DOI":"10.1016\/j.taap.2021.115825","article-title":"Microsomal triglyceride transfer protein inhibitor lomitapide-induced liver toxicity is ameliorated by Triiodothyronine treatment following improved bile homeostasis and \u03b2-oxidation","volume":"434","author":"Patel","year":"2021","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_37","first-page":"e56672","article-title":"Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)","volume":"131","author":"Nagy","year":"2018","journal-title":"J. Vis. Exp."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/978-1-4939-2929-0_5","article-title":"Oil Red O and Hematoxylin and Eosin Staining for Quantification of Atherosclerosis Burden in Mouse Aorta and Aortic Root","volume":"1339","author":"Dorado","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5428","DOI":"10.1210\/en.2010-0663","article-title":"Androgen Receptor-Dependent and Independent Atheroprotection by Testosterone in Male Mice","volume":"151","author":"Bourghardt","year":"2010","journal-title":"Endocrinology"},{"key":"ref_40","first-page":"7","article-title":"[Mechanism, treatment, and evaluation of obesity-induced insulin resistance and type 2 diabetes]","volume":"32","author":"Zhao","year":"2010","journal-title":"Zhongguo Yi Xue Ke Xue Yuan Xue Bao"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"114296","DOI":"10.1016\/j.jep.2021.114296","article-title":"Standardized root extract of Withania somnifera and Withanolide A exert moderate vasorelaxant effect in the rat aortic rings by enhancing nitric oxide generation","volume":"278","author":"Pathak","year":"2021","journal-title":"J. Ethnopharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"9308","DOI":"10.1038\/s41598-017-06721-y","article-title":"MicroRNA-204 promotes vascular endoplasmic reticulum stress and endothelial dysfunction by targeting Sirtuin1","volume":"7","author":"Kassan","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/CE.S174169","article-title":"Lomitapide: A review of its clinical use, efficacy, and tolerability","volume":"14","author":"Alonso","year":"2019","journal-title":"Core Evid."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1111\/cns.13961","article-title":"Lomitapide ameliorates middle cerebral artery occlusion-induced cerebral ischemia\/reperfusion injury by promoting neuronal autophagy and inhibiting microglial migration","volume":"28","author":"Zheng","year":"2022","journal-title":"CNS Neurosci. Ther."},{"key":"ref_45","first-page":"679","article-title":"Microvascular endothelial dysfunction in a young patient with familial hypercholesterolemia","volume":"130","author":"Pajkowski","year":"2020","journal-title":"Pol. Arch. Intern. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00246-013-0742-0","article-title":"Endothelial Dysfunction, But Not Structural Atherosclerosis, Is Evident Early in Children With Heterozygous Familial Hypercholesterolemia","volume":"35","author":"Vlahos","year":"2014","journal-title":"Pediatr. Cardiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.2337\/db11-1621","article-title":"Caloric Restriction Chronically Impairs Metabolic Programming in Mice","volume":"61","author":"Kirchner","year":"2012","journal-title":"Diabetes"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0021-9150(97)00165-2","article-title":"C57BL\/6 mice fed high fat diets as models for diabetes-accelerated atherosclerosis","volume":"136","author":"Schreyer","year":"1998","journal-title":"Atherosclerosis"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5551\/jat.44107","article-title":"Dietary Intake during 56 Weeks of a Low-Fat Diet for Lomitapide Treatment in Japanese Patients with Homozygous Familial Hypercholesterolemia","volume":"26","author":"Kameyama","year":"2019","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1440-1681.2011.05513.x","article-title":"Inhibition of microsomal triglyceride transfer protein improves insulin sensitivity and reduces atherogenic risk in Zucker fatty rats","volume":"38","author":"Dhote","year":"2011","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0021-9150(01)00721-3","article-title":"Microsomal triglyceride transfer protein: Does insulin resistance play a role in the regulation of chylomicron assembly?","volume":"160","author":"Phillips","year":"2002","journal-title":"Atherosclerosis"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/oby.22072","article-title":"The Obesity Epidemic: A Consequence of Reduced Energy Expenditure and the Uncoupling of Energy Intake?","volume":"26","author":"Church","year":"2018","journal-title":"Obesity"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1080\/10408390903372599","article-title":"Ten putative contributors to the obesity epidemic","volume":"49","author":"McAllister","year":"2009","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40292-016-0155-2","article-title":"Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk","volume":"23","author":"Rosei","year":"2016","journal-title":"High Blood Press. Cardiovasc. Prev."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/sj.ejcn.1602749","article-title":"Methodology for studying postprandial lipid metabolism","volume":"61","author":"Lairon","year":"2007","journal-title":"Eur. J. Clin. Nutr."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1248\/bpb.28.247","article-title":"Implitapide, a Microsomal Triglyceride Transfer Protein Inhibitor, Reduces Progression of Atherosclerosis in Apolipoprotein E Knockout Mice Fed a Western-Type Diet: Involvement of the Inhibition of Postprandial Triglyceride Elevation","volume":"28","author":"Ueshima","year":"2005","journal-title":"Biol. Pharm. Bull."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1161\/01.CIR.102.7.716","article-title":"Endothelial Dysfunction in Men With Small LDL Particles","volume":"102","author":"Vakkilainen","year":"2000","journal-title":"Circulation"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1161\/CIRCRESAHA.115.306301","article-title":"Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis","volume":"118","author":"Gimbrone","year":"2016","journal-title":"Circ. Res."}],"container-title":["Antioxidants"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3921\/12\/6\/1287\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:56:15Z","timestamp":1760126175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3921\/12\/6\/1287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,16]]},"references-count":58,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["antiox12061287"],"URL":"https:\/\/doi.org\/10.3390\/antiox12061287","relation":{},"ISSN":["2076-3921"],"issn-type":[{"type":"electronic","value":"2076-3921"}],"subject":[],"published":{"date-parts":[[2023,6,16]]}}}